CPRX

CATALYST PHARMACEUTICALS, INC.

CPRX · CIK 1369568 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$589M
20182025
Net Income$214M
20182025
Operating CF$209M
20182025
Free Cash Flow$209M
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue$0.6B$0.5B$0.4B$0.2B$0.1B$0.1B$0.0B$0.0B
Cost of Revenue$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B$0.0B—
Gross Profit————————
R&D Expense$0.0B$0.0B$0.1B$0.0B$0.0B$0.0B$0.0B$0.0B
SG&A Expense$0.2B$0.2B$0.1B$0.1B$0.0B$0.0B$0.0B—
Operating Income$0.3B$0.2B$0.1B$0.1B$0.1B$0.0B$0.0B$-0.0B
Net Income$0.2B$0.2B$0.1B$0.1B$0.0B$0.1B$0.0B$-0.0B
EPS (Basic)$1.75$1.38$0.67$0.80$0.38$0.72$0.08—
EPS (Diluted)$1.68$1.31$0.63$0.75$0.37$0.71$0.07—

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$1.1B$0.9B$0.5B$0.4B$0.2B$0.2B$0.1B$0.1B
Current Assets$0.9B$0.6B$0.2B$0.3B$0.2B$0.2B$0.1B$0.1B
Cash & Equivalents$0.7B$0.5B$0.1B$0.3B$0.2B$0.1B$0.1B$0.0B
Total Liabilities$0.1B$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B$0.0B
Current Liabilities$0.1B$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B$0.0B
Stockholders' Equity$1.0B$0.7B$0.4B$0.3B$0.2B$0.2B$0.1B$0.1B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$0.2B$0.2B$0.1B$0.1B$0.1B$0.0B$0.0B$-0.0B
Investing Cash Flow$-0.0B$-0.0B$-0.3B$0.0B$-0.0B$-0.0B$0.0B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$-0.0B$0.1B$-0.0B$0.0B$-0.0B$0.0B$0.0B$0.0B
← Companies